Skip to main content

Articles

ASH 2017 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated, High-Risk CLL and Relapsed/Refractory CLL: A Phase 2 Trial
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: Updated Results from the Phase 1/2 ACE-CL-001 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Economic Evaluation for the United States of Ibrutinib versus Allogeneic HSCT for Patients with Relapsed or Refractory CLL with 17p Deletion
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis
Read More
Page 78 of 245
Results 771 - 780 of 2441